Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The encapsulated yeast Cryptococcus neoformans is a significant cause of meningitis and death in patients with AIDS. Some murine monoclonal antibodies (MAbs) against the glucuronoxylomannan (GXM) component of the C. neoformans capsular polysaccharide can prolong the lives of infected mice, while others have no effect or can even shorten survival. To date, no one has systematically compared the efficacies of antibodies with the same variable regions and different human constant regions with their unique combination of effector functions in providing protection against murine C. neoformans infection. In the present study, we examined the efficacies of anti-GXM MAbs of the four human immunoglobulin G (IgG) subclasses, which have identical variable regions but differ in their capacities to bind the three types of Fc receptors for IgG (FcγR), their abilities to activate complement, and their half-lives. IgG2 and IgG4 anti-GXM prolonged the lives of infected BALB/c mice, IgG3 anti-GXM did not affect animal survival, while mice treated with IgG1 anti-GXM died earlier than mice treated with phosphate-buffered saline or irrelevant isotype-matched MAbs. All MAbs decreased serum GXM in infected animals. Effector pathways traditionally believed to be important in defense against microbes, such as opsonophagocytosis and complement binding, negatively correlated with antibody efficacy. It is generally accepted that human IgG1 has the most favorable combination of effector functions for therapeutic use against infections. Therefore, our findings have significant implications for humanization of the mouse IgG1 currently in clinical trials for cryptococcal meningitis and for the design of antibody therapeutics to treat other infectious diseases as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“Alterations in glycosylation can affect antibody function (27, 50, 57), as well as immunogenicity and clearance.”
BackgroundElliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682 · cited 1×
“Although recombinant-antibody-based therapies have recently been licensed for the treatment of tumors (66) and arterial thrombosis (64) and to effect immune suppression for inflammatory diseases and transplant rejection (18, 61), only one monoclonal antibody (MAb) (palivizumab) is currently available for therapeutic u…”
BackgroundParekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 1×
“Alterations in glycosylation can affect antibody function (27, 50, 57), as well as immunogenicity and clearance.”
BackgroundTucker, S. C., & Casadevall, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702799 · Cited by 306
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298 · cited 2×
“18B7, was chosen from a group of MAbs to GXM, as it was the most effective in protecting A/J mice against cryptococcal infection (8).”
BackgroundFlexibility of human IgG subclasses
Roux, K. H., Strelets, L., & Michaelsen, T. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3372 · Cited by 254
Pathogenesis of Cerebral Cryptococcus neoformans Infection after Fungemia
Chrétien, F., Lortholary, O., Kansau, I., Neuville, S., Gray, F., & Dromer, F. (2002) · The Journal of Infectious Diseases · doi:10.1086/341564 · Cited by 201
Santangelo, R., Zoellner, H., Sorrell, T., Wilson, C., Donald, C., Djordjevic, J., Shounan, Y., & Wright, L. (2004) · Infection and Immunity · doi:10.1128/iai.72.4.2229-2239.2004 · Cited by 169 · cited 1×
“neoformans to the brain (47), the nonprotective antibodies IgG1 and IgG3, which facilitate C.”
Background
Cited by
Carbohydrate vaccines: developing sweet solutions to sticky situations?
Astronomo, R. D., & Burton, D. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3012 · Cited by 629
Chapter 4 The Capsule of the Fungal Pathogen Cryptococcus neoformans
Zaragoza, O., Rodrigues, M. L., De Jesus, M., Frases, S., Dadachova, E., & Casadevall, A. (2009) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(09)01204-0 · Cited by 457
Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass
Dillon, T. M., Ricci, M. S., Vezina, C., Flynn, G. C., Liu, Y. D., Rehder, D. S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709988200 · Cited by 291
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198
Uppuluri, P., Singh, S., Alqarihi, A., Schmidt, C. S., Hennessey, J. P., Yeaman, M. R., Filler, S. G., Edwards, J. E., & Ibrahim, A. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01349 · Cited by 56
Metadata
- Authors
- Beenhouwer, D. O., Yoo, E. M., Lai, C.-W., Rocha, M. A., & Morrison, S. L.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2007-03
- Volume
- 75
- Issue
- 3
- Pages
- 1424-1435
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W2129063602
- Cited by
- 74
- References
- 9
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection. https://app.cochat.ai/papers/10.1128/iai.01161-06
- The paper
- Beenhouwer, D. O., Yoo, E. M., Lai, C.-W., Rocha, M. A., & Morrison, S. L. (2007). Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection. Infection and Immunity. https://doi.org/10.1128/iai.01161-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.